Background:
Globally, most patients with cancer are diagnosed after symptom onset. Accelerating diagnosis for symptomatic patients can improve treatment, care experience, and survival. However, achieving timely diagnosis while reducing persistent sociodemographic inequalities is complex and requires coordinated public health and health?system responses.
Objectives: 
To distil transferable lessons for global health systems by synthesising population?based research evidence generated through early cancer diagnosis policies and research programmes in the UK, during the 25-year period 2001–2026.
Methods: 
A thematic overview of published population?based research alongside a documentary analysis of key policy documents, including two national cancer plans/strategies, a national early diagnosis strategy, and national clinical guidelines for the investigation of suspected cancer in primary care.
Results: 
Following the introduction of fast?track referral pathways for suspected cancer in 2001, national clinical guidelines for suspected cancer in primary care were issued in 2005 by the National Institute for Health and Care Excellence (NICE) – and subsequently revised in 2015. The 2008 National Awareness and Early Diagnosis Initiative stimulated a series of population?based surveys examining cancer symptom awareness and barriers and enablers to prompt help?seeking, which informed the development of sustained social?marketing public health interventions to encourage earlier presentation. Major investments in cancer registration and cancer data infrastructure led to high and stable completeness of stage at diagnosis from 2014 onwards. In parallel, a novel “routes to diagnosis” framework was developed (2011–2012) to enable ongoing monitoring of elective symptomatic, screening, and emergency diagnostic pathways, and related patient group inequalities. Evidence from this work, demonstrating that over 90% of cancers are diagnosed symptomatically, catalysed a sustained research effort into the prognostic value of presenting features. This research initially focused on characterising the predictive value of presenting symptoms and subsequently the predictive value of combinations of symptoms with blood test results, and increasing attention to non?specific symptoms. From around 2006, the proportion of emergency cancer diagnoses declined rapidly until 2016, but since plateaued, with substantial and persistent inequalities. Escalating volumes of fast?track referrals have raised concerns regarding sustainability and cost?effectiveness, such referrals rising from 0.9M to ~3M annually within a 15-year period. More recently, dedicated referral pathways for patients with non?specific symptoms have been piloted and subsequently incorporated into routine diagnostic options in the early 2020s.
Conclusions/Implications: 
The UK experience highlights the critical importance for governments developing early diagnosis strategies or national cancer plans to invest in public health surveillance and robust data infrastructures that enable evaluation of policy impact and monitoring of inequalities over time. A typology (“toolkit”) of policy components and approaches to developing and introducing early diagnosis policies and guiding their subsequent ongoing evaluation will be presented to support informed adaptation and transfer of lessons to both resource?rich and resource?constrained settings.